Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

844 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C, Hoekman K, Bowman A, Vermorken JB, Anthoney A, Smyth J, van Kesteren C, Beijnen JH, Uiters J, Wanders J, Gomez J, Guzmán C, Jimeno J, Hanauske A. Twelves C, et al. Among authors: guzman c. Eur J Cancer. 2003 Sep;39(13):1842-51. doi: 10.1016/s0959-8049(03)00458-1. Eur J Cancer. 2003. PMID: 12932661 Clinical Trial.
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
van Kesteren C, Twelves C, Bowman A, Hoekman K, López-Lázaro L, Jimeno J, Guzman C, Mathôt RA, Simpson A, Vermorken JB, Smyth J, Schellens JH, Hillebrand MJ, Rosing H, Beijnen JH. van Kesteren C, et al. Among authors: guzman c. Anticancer Drugs. 2002 Apr;13(4):381-93. doi: 10.1097/00001813-200204000-00007. Anticancer Drugs. 2002. PMID: 11984084 Clinical Trial.
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
van Kesteren C, Mathĵt RA, López-Lázaro L, Cvitkovic E, Taamma A, Jimeno JM, Guzman C, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH. van Kesteren C, et al. Among authors: guzman c. Cancer Chemother Pharmacol. 2001 Dec;48(6):459-66. doi: 10.1007/s002800100368. Cancer Chemother Pharmacol. 2001. PMID: 11800026
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD. Garcia-Carbonero R, et al. Among authors: guzman c. J Clin Oncol. 2004 Apr 15;22(8):1480-90. doi: 10.1200/JCO.2004.02.098. J Clin Oncol. 2004. PMID: 15084621 Clinical Trial.
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG. Puchalski TA, et al. Among authors: guzman c. Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19. doi: 10.1007/s00280-002-0498-3. Epub 2002 Jul 31. Cancer Chemother Pharmacol. 2002. PMID: 12357306 Clinical Trial.
844 results